Payment overview · 2025
General Payments
$2,160.27
141 reported records · 19 companies
Healthcare provider profile · identity verified
Eric Christopher Poston, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · SWEETWATER, TN · NPI 1487652624
Verified facts
What the public records show
CMS Open Payments records show Eric Christopher Poston, M.D. received $2,160.27 in general payments during 2025 across 141 reported records.
PFIZER INC. accounted for 16.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 32 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Linzess, Mounjaro, Ozempic, Prolia, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Linzess by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Prolia by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 135 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 127 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 114 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 256 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $360.88 | 16.7% | 29 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $214.12 | 9.9% | 16 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $201.74 | 9.3% | 15 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $194.74 | 9.0% | 11 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $190.19 | 8.8% | 8 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $171.41 | 7.9% | 8 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $168.27 | 7.8% | 14 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $164.93 | 7.6% | 11 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $135.09 | 6.2% | 9 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $95.19 | 4.4% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $71.96 | 3.3% | 4 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $50.63 | 2.3% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $36.88 | 1.7% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $26.26 | 1.2% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$21.57 | 1.0% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $18.78 | 0.9% | 1 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $17.62 | 0.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.13 | 0.7% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $5.88 | 0.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,160.27 | 141 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $360.88 | 29 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $214.12 | 16 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $203.82 | 16 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $171.41 | 8 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $164.93 | 11 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $162.48 | 11 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $157.06 | 13 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $145.64 | 9 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $138.23 | 8 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $135.09 | 9 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $127.02 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $98.95 | 9 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $95.19 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $85.38 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $77.98 | 7 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $71.96 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $71.96 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $63.17 | 4 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $54.24 | 4 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $50.63 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $49.10 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $39.26 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $36.88 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $35.05 | 3 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $33.39 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $26.26 | 1 | 2025 |
Source payment records
|
|||||
| INTELLIS ADAPTIVESTIM Normalized: intellis adaptivestim |
Device | Medtronic, Inc. | $21.57 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $18.78 | 1 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $17.62 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $14.83 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.13 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $5.88 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 256 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 135 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 46 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 114 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 69 | exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 127 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
46 | 11 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
135 | 27 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
43 | 17 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
127 | 29 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
61 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
114 | 24 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
69 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
256 | 54 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 976 | 256 |
| Amlodipine Besylate | Amlodipine Besylate | 656 | 175 |
| Lisinopril | Lisinopril | 541 | 149 |
| Levothyroxine Sodium | Levothyroxine Sodium | 514 | 118 |
| Pantoprazole Sodium | Pantoprazole Sodium | 448 | 121 |
| Losartan Potassium | Losartan Potassium | 431 | 118 |
| Carvedilol | Carvedilol | 375 | 98 |
| Gabapentin | Gabapentin | 375 | 68 |
| Omeprazole | Omeprazole | 353 | 82 |
| Potassium Chloride | Potassium Chloride | 351 | 91 |
| Furosemide | Furosemide | 319 | 90 |
| Glimepiride | Glimepiride | 316 | 79 |
| Escitalopram Oxalate | Escitalopram Oxalate | 293 | 63 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 292 | 72 |
| Allopurinol | Allopurinol | 285 | 79 |
| Fenofibrate | Fenofibrate | 266 | 71 |
| Metformin Hcl | Metformin Hcl | 259 | 76 |
| Eliquis | Apixaban | 256 | 54 |
| Metoprolol Tartrate | Metoprolol Tartrate | 247 | 61 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 245 | 72 |
| Ezetimibe | Ezetimibe | 241 | 62 |
| Hydrochlorothiazide | Hydrochlorothiazide | 234 | 67 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 232 | 39 |
| Tamsulosin Hcl | Tamsulosin Hcl | 230 | 56 |
| Trazodone Hcl | Trazodone Hcl | 227 | 38 |
| Montelukast Sodium | Montelukast Sodium | 222 | 48 |
| Clopidogrel | Clopidogrel Bisulfate | 221 | 69 |
| Meloxicam | Meloxicam | 210 | 50 |
| Duloxetine Hcl | Duloxetine Hcl | 207 | 52 |
| Fluticasone Propionate | Fluticasone Propionate | 205 | 76 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 195 | 54 |
| Tramadol Hcl | Tramadol Hcl | 187 | 54 |
| Levofloxacin | Levofloxacin | 171 | 114 |
| Donepezil Hcl | Donepezil Hcl | 169 | 43 |
| Pravastatin Sodium | Pravastatin Sodium | 144 | 43 |
| Zolpidem Tartrate | Zolpidem Tartrate | 142 | 17 |
| Alendronate Sodium | Alendronate Sodium | 137 | 34 |
| Farxiga | Dapagliflozin Propanediol | 135 | 27 |
| Hydralazine Hcl | Hydralazine Hcl | 132 | 31 |
| Ropinirole Hcl | Ropinirole Hcl | 132 | 24 |
| Metoprolol Succinate | Metoprolol Succinate | 131 | 40 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 127 | 29 |
| Clonidine Hcl | Clonidine Hcl | 126 | 29 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 121 | 33 |
| Pregabalin | Pregabalin | 120 | 20 |
| Bupropion Xl | Bupropion Hcl | 117 | 33 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 115 | 30 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 114 | 44 |
| Mounjaro | Tirzepatide | 114 | 24 |
| Cefdinir | Cefdinir | 112 | 99 |
| Methylprednisolone | Methylprednisolone | 111 | 85 |
| Metformin Hcl Er | Metformin Hcl | 110 | 35 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 109 | 32 |
| Simvastatin | Simvastatin | 109 | 31 |
| Alprazolam | Alprazolam | 101 | 11 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 94 | 19 |
| Tizanidine Hcl | Tizanidine Hcl | 91 | 18 |
| Ondansetron Hcl | Ondansetron Hcl | 89 | 32 |
| Fenofibrate | Fenofibrate,micronized | 87 | 25 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 84 | 69 |
| Ramipril | Ramipril | 76 | 19 |
| Sertraline Hcl | Sertraline Hcl | 76 | 22 |
| Levetiracetam | Levetiracetam | 75 | 13 |
| Benazepril Hcl | Benazepril Hcl | 69 | 13 |
| Ozempic | Semaglutide | 69 | 13 |
| Warfarin Sodium | Warfarin Sodium | 62 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 61 | 17 |
| Jardiance | Empagliflozin | 61 | 12 |
| Chlorthalidone | Chlorthalidone | 58 | 17 |
| Memantine Hcl | Memantine Hcl | 57 | 14 |
| Celecoxib | Celecoxib | 54 | 14 |
| Lovastatin | Lovastatin | 53 | 13 |
| Topiramate | Topiramate | 52 | suppressed |
| Xarelto | Rivaroxaban | 51 | suppressed |
| Lorazepam | Lorazepam | 50 | 15 |
| Famotidine | Famotidine | 48 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 48 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 48 | 11 |
| Digoxin | Digoxin | 47 | suppressed |
| Linzess | Linaclotide | 46 | 11 |
| Rizatriptan | Rizatriptan Benzoate | 46 | 11 |
| Spiriva Respimat | Tiotropium Bromide | 46 | suppressed |
| Metolazone | Metolazone | 44 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 43 | 12 |
| Symbicort | Budesonide/Formoterol Fumarate | 43 | 17 |
| Bumetanide | Bumetanide | 42 | suppressed |
| Prednisone | Prednisone | 42 | 17 |
| Spironolactone | Spironolactone | 42 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 41 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 40 | suppressed |
| Finasteride | Finasteride | 40 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 39 | 30 |
| Promethazine Hcl | Promethazine Hcl | 39 | 15 |
| Valacyclovir | Valacyclovir Hcl | 38 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 36 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 36 | 15 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 35 | 11 |
| Clonazepam | Clonazepam | 34 | suppressed |
| Trulicity | Dulaglutide | 34 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 33 | 11 |
| Olanzapine | Olanzapine | 32 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Cephalexin | Cephalexin | 30 | 27 |
| Fluconazole | Fluconazole | 30 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 30 | suppressed |
| Novolog Flexpen | Insulin Aspart | 30 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 30 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 29 | suppressed |
| Primidone | Primidone | 29 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 29 | 23 |
| Baclofen | Baclofen | 28 | suppressed |
| Mupirocin | Mupirocin | 28 | 19 |
| Myrbetriq | Mirabegron | 28 | suppressed |
| Repatha Sureclick | Evolocumab | 28 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 28 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 27 | suppressed |
| Entresto | Sacubitril/Valsartan | 27 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 27 | suppressed |
| Glipizide | Glipizide | 26 | suppressed |
| Clotrimazole | Clotrimazole | 25 | suppressed |
| Valsartan | Valsartan | 25 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 24 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Atenolol | Atenolol | 23 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 22 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 20 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 19 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 19 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | 11 |
| Unifine Pentips | Pen Needle, Diabetic | 19 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 18 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 18 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 18 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 17 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 17 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 17 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Ibuprofen | Ibuprofen | 17 | suppressed |
| Irbesartan | Irbesartan | 17 | suppressed |
| Levemir | Insulin Detemir | 17 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 17 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 16 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 16 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 16 | 11 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 16 | suppressed |
| Mirtazapine | Mirtazapine | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 15 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 15 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Metronidazole | Metronidazole | 15 | 13 |
| Dilt-Xr | Diltiazem Hcl | 14 | suppressed |
| Estradiol | Estradiol | 14 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 14 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 13 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 13 | suppressed |
| Isentress | Raltegravir Potassium | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Levemir Flexpen | Insulin Detemir | 13 | suppressed |
| Brilinta | Ticagrelor | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Clonidine | Clonidine | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 12 | suppressed |
| Ranolazine Er | Ranolazine | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 12 | suppressed |
| Calcitriol | Calcitriol | 11 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 11 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 11 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Hydroxyurea | Hydroxyurea | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Premarin | Estrogens, Conjugated | 11 | suppressed |
| Prolia | Denosumab | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
| Vascepa | Icosapent Ethyl | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,160.27 · 141 records | PFIZER INC. | AIRSUPRA, AREXVY, Auvelity, BREZTRI, CAPLYTA, CREON, Cologuard Collection Kit, ELIQUIS, EVENITY, FARXIGA, GVOKE HYPOPEN, INTELLIS ADAPTIVESTIM, Kerendia, LINZESS, LifeVest, MOUNJARO, NEXLETOL, NURTEC ODT, OTEZLA, Ozempic, PROLIA, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, VOQUEZNA, VRAYLAR, VYEPTI, Veozah, Wegovy, ZAVZPRET, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error